Member Info for wiseys

For a considered view worth reading this note out today with a BUY and 52p PT .....highlights the true potential and the path forward..

https://www.trinitydelta.org/research-notes/commercialising-cutting-edge-diagnostics/

A 'death spiral' is usually associated with companies that are saddled with onerous debt finance...think OBD has enough cash until April....

Can you read?!!...cash position excludes the fund raise and they have included sales to date..

Really couldn't care about Transform trial...don't get why so hung up on it...the main focus is US...they've always been clear about that...meanwhile London Clinic and Goodboody distribution deals are undoubtedly good news for UK strategy for those who care about what is a relatively small market in the grand scheme of things..

..think you'll find the target is 1,000 per month not per day...."The PSE vertical is led by Dr Steve Arrivo, who joined the Company in November 2023 as Senior Vice President of Business and Corporate Development. Through the remainder of 2024 and beyond, the Company's commercial team will have a focus on large accounts, particularly including concierge medicine cash-pay customers, as the quickest way both to increase sales volumes and positively impact cash flow (the test has a price of $950 and the team is seeking to increase orders to a level of 1,000 tests per month). In addition, the Company will seek national distribution partners to make the test more readily accessible across the whole of the US and utilise available capacity at the Company's CLIA-registered lab."

@pompal..the other scenario is they'll hit the sales target which is £12m of revenue p.a. from PSE alone and which covers the cash burn and assumes 0 sales from CIRT or any disposals...all to play for at these levels..

£10.25m if include PrimaryBid offer but the 'not less than £9m' is the important bit

Wrong, they wanted £9m and they got £9.9m ...a good result in this market

10 min 20 secs in Dr comments 'excited to be able to start offering PSE in my clinic this month and have already taken client orders'....seems like orders going in the right direction!

Https://intheloop.oxfordbiodynamics.com/blog/unveiling-expert-insights-on-the-pse-test-with-dr-pohlman-and-dr-heaton?utm_medium=social%20&utm_campaign=feb-post

Https://bioquicknews.com/new-liquid-biopsy-test-can-improve-prostate-cancer-test-accuracy-from-55-to-94-revolutionary-test-based-on-3d-genomics-is-described-at-precision-medicine-world-conference-pmwc-2024/#more-13635

Reading some of these posts it does amaze me how few people realise that regardless of how amazing a new product could be it takes time for it to be adopted by medical communities. As Jon Burrows said, they're not selling widgets. PSE has only just been launched. If Steve Arrivo gets anywhere near his sales target of 2,500 tests per month then we'll have nothing to worry about and that's before we factor in that they're looking for partners to help scale which could come any day. It's interesting that so far there's been no significant institutional selling we're aware of via TR1's which tells me this the sensible bigger shareholders are sticking with it and are probably rubbing their hands with glee at the prospect of being able to top up on the back of this retail panic sell off

Remember the Oct 22 placing that they did at a 35% PREMIUM....just think about that for a moment...they got that away before the PSE test had been approved...prospects are much better today

Even if that was the case I can't think of a fund raise that would be more oversubscribed given the potential on offer here...load up

OBD are presenting at the Jefferies HC conference this week. Should generate some investor interest https://www.lse.co.uk/ShareChat.html?ShareTicker=OBD&share=Oxford-Biodyn#posting-rules

Would be helpful to know what the 'market expectations' are!? I don't think there are any updated broker forecasts in the market......some detailed research on the potential is needed..

All round excellent news and would expect brokers to upgrade forecasts post July update...good to see DX back on top

Agreed....still has $80m of debt...perfect opportunity for company to hit the market with a dilutive fundraise IMO..agree with TW over at Shareprohets on this one..take your profit and head for the hills!

It was held in James Hanburys not Cripsin Odeys fund...a block of 27m or £9m worth went through on Friday...wouldn't be surprised if Odey has already sold...

Can see this going bust...net debt of $80m and only $11m of cash which it's churning through at $1.5m month.....surely they have to comment on this dire situation in the results? Tin hat time....